{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:04:32Z","timestamp":1782846272935,"version":"3.54.5"},"reference-count":51,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Internet Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec sec-type=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adherence to antiseizure medications (ASMs) is a cornerstone of effective epilepsy management. However, current consensus guidelines for assessing medication adherence via therapeutic drug monitoring (TDM) may neglect individual patient characteristics, thereby compromising the accuracy of adherence assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"objective\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study proposed an innovative Bayesian\u2013based pharmacokinetic (PK) framework integrated with TDM data to address the above limitations, with a focus on 14 widely prescribed ASMs, including brivaracetam, carbamazepine, clobazam, eslicarbazepine acetate, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, phenobarbital, topiramate, valproic acid, vigabatrin, and zonisamide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Comprehensive clinical trial simulations were conducted to investigate the PK of ASMs in patients with epilepsy under conditions of full adherence and various nonadherent dosing behaviors, including omission of the last dose and consecutive missed doses. Bayesian posterior probabilities of these dosing behaviors were derived by integrating validated population PK models, individual patient demographics (eg, age, weight, creatinine clearance), dosing history, prior adherence probabilities and TDM measurements. Additionally, the influence of covariates on assessment outcomes was systematically evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The Bayesian-based PK approach demonstrated robust discriminative ability. Under idealized simulation conditions with minimized variabilities, the approach achieved accurate retrodiction of the last 1 or 2 doses across all 14 ASMs and partial retrodiction of extended nonadherence trajectories for 6 ASMs. Concentration thresholds for adherence classification varied significantly across drugs and are influenced by patient-specific factors, comedications, formulation, sampling time, and prior probability. To translate these insights into practice, an adaptable web-based dashboard was developed using the\n                      <jats:italic>shiny<\/jats:italic>\n                      package in R software to enable precise and real-time assessments of medication adherence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study establishes a Bayesian-based PK approach to enhance the assessment of ASMs adherence. This approach facilitates a paradigm shift from population-based management to patient-specific adherence profiling, offering a practical methodology for the precise evaluation of medication-taking behaviors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/77917","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T18:41:47Z","timestamp":1767724907000},"page":"e77917-e77917","source":"Crossref","is-referenced-by-count":2,"title":["Bayesian-Based Pharmacokinetic Framework Integrated with Therapeutic Drug Monitoring for Assessing Adherence to Antiseizure Medications: A Clinical Trial Simulation Study"],"prefix":"10.2196","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3615-3274","authenticated-orcid":false,"given":"Xiao-Qin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6740-6003","authenticated-orcid":false,"given":"Zi-Ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4977-1642","authenticated-orcid":false,"given":"Wei-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2633-6766","authenticated-orcid":false,"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5591-1334","authenticated-orcid":false,"given":"Fu-Qing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6429-3178","authenticated-orcid":false,"given":"Jun-Jie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7999-7162","authenticated-orcid":false,"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"3","key":"R1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","journal-title":"Epilepsia"},{"issue":"4","key":"R2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011412.pub4","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","volume":"4","author":"Nevitt","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"R3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/14737167.2024.2349191","article-title":"Nonadherence to antiseizure medications: what have we learned and what can be done next?","volume":"24","author":"Al-Aqeel","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"R4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/ane.12703","article-title":"A review of medication adherence in people with epilepsy","volume":"135","author":"Malek","journal-title":"Acta Neurol Scand"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2806341","article-title":"Medication belief and adherence among patients with epilepsy","volume":"2019","author":"Niriayo","journal-title":"Behav Neurol"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110544","article-title":"Global patterns and predictors of anti-seizure medication adherence in pediatric epilepsy: A systematic review and meta-analysis","volume":"172","author":"Adisu","journal-title":"Epilepsy Behav"},{"issue":"20","key":"R7","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1212\/01.wnl.0000319693.10338.b9","article-title":"Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study","volume":"71","author":"Faught","journal-title":"Neurology"},{"issue":"3","key":"R8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1528-1167.2008.01794.x","article-title":"Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study","volume":"50","author":"Faught","journal-title":"Epilepsia"},{"issue":"3","key":"R9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/bcp.16384","article-title":"Medication adherence-Everybody\u2019s problem but nobody\u2019s responsibility?","volume":"91","author":"Chan","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"R10","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","journal-title":"Ther Drug Monit"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2014.09.069","article-title":"The benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy","volume":"42","author":"Stepanova","journal-title":"Epilepsy Behav"},{"issue":"1-2","key":"R12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke","journal-title":"Pharmacopsychiatry"},{"issue":"10","key":"R13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/17425255.2020.1806236","article-title":"Pharmacokinetic considerations about antiseizure medications in the elderly","volume":"16","author":"Roberti","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"R14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40262-019-00845-2","article-title":"Therapeutic drug monitoring of antiepileptic drugs in women with epilepsy before, during, and after pregnancy","volume":"59","author":"Arfman","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"R15","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13793","article-title":"Sources of pharmacokinetic and pharmacodynamic variability and clinical pharmacology studies of antiseizure medications in the pediatric population","volume":"17","author":"Maglalang","journal-title":"Clin Transl Sci"},{"issue":"4","key":"R16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10928-022-09812-0","article-title":"Should patients skip late doses of medication? A pharmacokinetic perspective","volume":"49","author":"Clark","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"R17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10928-023-09897-1","article-title":"How drug onset rate and duration of action affect drug forgiveness","volume":"51","author":"Clark","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9","key":"R18","doi-asserted-by":"publisher","first-page":"e921","DOI":"10.1212\/WNL.0000000000201604","article-title":"Handling delayed or missed dose of antiseizure medications: a model-informed individual remedial dosing","volume":"100","author":"Li","journal-title":"Neurology"},{"issue":"3","key":"R19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10928-011-9196-2","article-title":"A Bayesian approach for the estimation of patient compliance based on the last sampling information","volume":"38","author":"Barri\u00e8re","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"R20","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/cpt.1707","article-title":"Adherence and population pharmacokinetic properties of amodiaquine when used for seasonal malaria chemoprevention in african children","volume":"107","author":"Ding","journal-title":"Clin Pharmacol Ther"},{"key":"R21","unstructured":"Nick H . Simulations with\/without residual error. The Mail Archive. 2009. URL: https:\/\/www.mail-archive.com\/nmusers@globomaxnm.com\/msg01817.html [Accessed 30-11-2025]"},{"issue":"3","key":"R22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2710.2004.00557.x","article-title":"Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data","volume":"29","author":"Jiao","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"R23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/FTD.0b013e318030def0","article-title":"Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese","volume":"29","author":"Goto","journal-title":"Ther Drug Monit"},{"issue":"6","key":"R24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2165\/00003088-200746060-00004","article-title":"Population pharmacokinetics of levetiracetam in Japanese and Western adults","volume":"46","author":"Pigeolet","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"R25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/FTD.0b013e31817d842a","article-title":"Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance","volume":"30","author":"Okada","journal-title":"Ther Drug Monit"},{"issue":"5","key":"R26","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/j.1528-1167.2008.01974.x","article-title":"Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy","volume":"50","author":"Chhun","journal-title":"Epilepsia"},{"issue":"10","key":"R27","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1111\/j.1528-1167.2010.02598.x","article-title":"Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age","volume":"51","author":"Girgis","journal-title":"Epilepsia"},{"issue":"11","key":"R28","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40262-014-0172-z","article-title":"Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms","volume":"53","author":"Nielsen","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"R29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/FTD.0000000000000015","article-title":"Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy","volume":"36","author":"Saruwatari","journal-title":"Ther Drug Monit"},{"issue":"3","key":"R30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0212-8","article-title":"A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation","volume":"54","author":"Ding","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"R31","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/jcph.761","article-title":"Brivaracetam population pharmacokinetics and exposure\u2010response modeling in adult subjects with partial\u2010onset seizures","volume":"56","author":"Schoemaker","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"R32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00228-017-2230-6","article-title":"Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years","volume":"73","author":"Schoemaker","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"R33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/ane.12950","article-title":"Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate","volume":"138","author":"Gidal","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"R34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s10928-018-9596-7","article-title":"Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizures","volume":"45","author":"Sunkaraneni","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"R35","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ane.12874","article-title":"Pharmacokinetic\/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures","volume":"137","author":"Takenaka","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"R36","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40262-017-0614-5","article-title":"Effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for maintenance dose optimisation in future clinical trials","volume":"57","author":"van Dijkman","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"R37","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00228-018-2600-8","article-title":"Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens","volume":"75","author":"Lin","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"R38","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/FTD.0000000000000644","article-title":"Glomerular filtration rate is a major predictor of clearance of oxcarbazepine active metabolite in adult Chinese epileptic patients: a population pharmacokinetic analysis","volume":"41","author":"Lin","journal-title":"Ther Drug Monit"},{"issue":"4","key":"R39","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/jcph.1340","article-title":"Population pharmacokinetics of adjunctive lacosamide in pediatric patients with epilepsy","volume":"59","author":"Winkler","journal-title":"J Clin Pharmacol"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2018.10.011","article-title":"Modeling and simulation for the evaluation of dose adaptation rules of intravenous lacosamide in children","volume":"149","author":"Winkler","journal-title":"Epilepsy Res"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105610","article-title":"Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy","volume":"169","author":"Wang","journal-title":"Pharmacol Res"},{"issue":"4","key":"R42","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040811","article-title":"Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients","volume":"14","author":"Teixeira-da-Silva","journal-title":"Pharmaceutics"},{"issue":"3","key":"R43","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/bcp.15572","article-title":"Population pharmacokinetics and dosing regimen optimization of levetiracetam in epilepsy during pregnancy","volume":"89","author":"Li","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"R44","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/epi.17954","article-title":"Population pharmacokinetics and dosing optimization of perampanel in children with epilepsy: A real-world study","volume":"65","author":"Li","journal-title":"Epilepsia"},{"key":"R45","unstructured":"Pharmacokinetic-based bayesian approach to assess medication adherence. MIPD. URL: https:\/\/mipd.shinyapps.io\/adherence_ASM\/ [Accessed 30-11-2025]"},{"issue":"1","key":"R46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/psp4.12366","article-title":"Children are not small adults, but can we treat them as such?","volume":"8","author":"Krekels","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"R47","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamaneurol.2021.5487","article-title":"Antiseizure medication concentrations during pregnancy: results from the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study","volume":"79","author":"Pennell","journal-title":"JAMA Neurol"},{"issue":"5","key":"R48","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/cns.13796","article-title":"Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy","volume":"28","author":"Yin","journal-title":"CNS Neurosci Ther"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107993","article-title":"Use of extended-release and immediate-release anti-seizure medications with a long half-life to improve adherence in epilepsy: a guide for clinicians","volume":"120","author":"Gidal","journal-title":"Epilepsy Behav"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2024.09.010","article-title":"Pricing dynamics of anti-seizure medications in the U.S","volume":"122","author":"Javarayee","journal-title":"Seizure"},{"issue":"1","key":"R51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10928-012-9285-x","article-title":"Compliance spectrum as a drug fingerprint of drug intake and drug disposition","volume":"40","author":"Barri\u00e8re","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["Journal of Medical Internet Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jmir.org\/2026\/1\/e77917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:10:16Z","timestamp":1782843016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmir.org\/2026\/1\/e77917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":51,"URL":"https:\/\/doi.org\/10.2196\/77917","relation":{},"ISSN":["1438-8871"],"issn-type":[{"value":"1438-8871","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"v28i3e77917"}}